Sensenig Bethany 4

What Happened
Bethany Sensenig, a director of Supernus Pharmaceuticals, was granted two awards of restricted stock units (RSUs) on February 18, 2026: 2,989 RSUs and 4,977 RSUs, totaling 7,966 RSUs. Each grant was reported at $0.00 (no cash paid) and is recorded as a derivative award that will convert into common shares upon vesting.

Key Details

• Transaction date: February 18, 2026 (filing date: Feb 20, 2026 — timely).
• Grant details: 2,989 RSUs and 4,977 RSUs (total 7,966 RSUs); reported acquisition code A (award/grant). Reported price: $0.00.
• Vesting/settlement: These RSUs will be settled in common stock upon vesting on February 18, 2027 (footnotes state each RSU equals one share).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 = each RSU converts to one share on vesting; F2 = settlement in common stock on 2/18/2027; F3 references option vesting on 2/18/2027 but no option grant is shown in this report.
• Timeliness: Filing appears timely (reported within two days of the transaction).

Context
RSU grants are compensation awards, not open-market purchases or sales. They generally do not produce immediate share ownership or cash proceeds until vesting and settlement, and they may be forfeitable if vesting conditions aren’t met. This filing documents the grant; it does not by itself indicate buying or selling pressure from the insider.